



## COMPANY DESCRIPTION

FORMYCON is a leading and independent developer of high-quality biopharmaceutical medicines, especially biosimilars. These are follow-on versions of biopharmaceuticals, for which exclusivity has expired. FORMYCON focuses on treatments in ophthalmology, immunology and on other key chronic diseases and currently has four biosimilars in development. Because of their size and structural complexity, and their production using living cell systems, biosimilars require very significant time, effort and expertise, both in their development and in their subsequent production. Based on its extensive experience in the development of biopharmaceutical medicines, FORMYCON is also working on the development of antibody-based COVID-19 compounds.

PIPELINE	Reference Product Active Ingredient Disease Area	Indications	Partner	Preclinical Phase	Clinical Phase I	Clinical Phase III
<b>FYB</b> <b>201</b>	Lucentis® Ranibizumab Ophthalmology	wAMD, DME, RVO, mCNV, DR*	Bioeq AG	✓	✓	
<b>FYB</b> <b>202</b>	Stelara® Ustekinumab Immunology	Pso, PsA, CD, UC	Aristo Pharma GmbH	✓		
<b>FYB</b> <b>203</b>	Eylea® Aflibercept Ophthalmology	wAMD, DME, RVO, DR*, mCNV**	Klinge Biopharma GmbH			
<b>FYB</b> <b>206</b>						

\* FDA approved only \*\* EMA approved only

## STRATEGY & GOALS

FORMYCON is specifically concentrating on the “third wave” of biosimilars, namely follow-on products for blockbuster biopharmaceuticals with patent expiries beginning in the year 2020. The company seeks to license out its biosimilar candidates to cooperation partners once certain defined development milestones have been attained to further develop these through to regulatory approval together with the respective partner company. The FORMYCON Group is currently focusing on research and development activities for both its own and out-licensed biosimilar projects, which are the source of its current revenues. After successful approval of the biosimilar candidates, FORMYCON will also participate in the subsequent marketing revenues. Because FORMYCON has focused its efforts on this generation of biosimilars at a timely stage, the company has been able to carve out for itself a unique and leading position in this market space. It's the strategic goal to further strengthen that status and, as a leading independent developer of biosimilars, to assume a key role in this global market. Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments. Through its biosimilars, FORMYCON will help not only patients around the world but also contributes to ease the financial strains on the world's healthcare systems.

## FACTS

<b>Founded</b>	2007
<b>Headquarters</b>	Planegg / Munich
<b>Employees</b>	> 100
<b>Management</b>	Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combe (CFO) Dr. Stefan Glombitz (COO)
<b>Supervisory Board</b>	Dr. Olaf Stiller (Chairman) Hermann Vogt (Deputy Chairman) Peter Wendeln (Member Supervisory Board)

## KEY FINANCIALS (in € million)

	2016	2017	2018	2019
<b>Revenue</b>	19.5	29.4	43.0	33.2
<b>EBITDA</b>	-4.1	-1.5	7.1	-1.4
<b>Net Income</b>	-4.1	-1.6	7.1	-2.3
<b>Equity Ratio (in %)</b>	82.9	82.9	83.9	90.0

## LATEST NEWS 2020

NOV 2020	Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara® (Ustekinumab)
NOV 2020	Formycon informs about the modified BLA-Submission Strategy for its Lucentis(R)* Biosimilar-Candidate FYB201
NOV 2020	Formycon Announces Virtual Annual General Meeting for December 10, 2020
OCT 2020	Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation
OCT 2020	Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million
SEP 2020	Formycon Announces Half-Year Results for 2020
AUG 2020	Formycon and Bioeq Enroll First Patient in Phase III Study with Aflibercept Biosimilar (FYB203)

## FINANCIAL CALENDAR

Publication of Annual Report 2019	May 18, 2020
Statement Q1 / 2020	June 22, 2020
Publication of Half-Year Report 2020	September 23, 2020
Statement Nine-Month Figures 2020	November 11, 2020
Annual General Meeting 2020	December 10, 2020

## MARKET DATA

ISIN	DE000A1EWVY8
Market Segment	Frankfurt, Stock Exchange „Scale“
Market Capitalization	~ € 330 million
Outstanding Shares	11,000,000
Shareholder Structure	15 % Institutional Investors 35 % Family Offices 15 % Founders and Management 35 % Free Float